Reply to "Weekly paclitaxel in elderly breast cancer patients", by C. Smorenburg et al. (Ann Oncol 2005; 16: 1979) [2]

Annals of Oncology

Volumn 16, Issue 12, 2005, Pages 1979-1980

  Del Mastro, L ^a   Perrone, F ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b NCI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIRUBICIN; MITOXANTRONE; PACLITAXEL;

AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; COMORBIDITY; CORRELATION FUNCTION; FREQUENCY ANALYSIS; GERIATRIC CARE; HEART INJURY; HUMAN; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 28444499709     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi387     Document Type: Letter

References (5)

1. Del Mastro L, Perrone F, Repetto L et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: A phase II study of the Gruppo Italiano di Oncologia Geriatria (GIOGer). Ann Oncol 2005; 16: 253-258.
2. Zambetti M, Moliterni A, Materazzo C et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001; 19: 37-43.
3. Bonneterre J, Rocheè H, Kerbrat P et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 2004; 22: 3070-3079.
4. Venturini M, Michelotti A, Del Mastro L et al. Multicenter randomized controlled clinical trial to evacuate cardioprotection with dexrazoxane versus no cardioprotection in women receiving chemotherapy for advanced breast cancer. J Clin Oncol 1996; 14: 3112-3120.
5. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-905.